Shaomeng J. Wang
#159,855
Most Influential Person Now
Shaomeng J. Wang's AcademicInfluence.com Rankings
Shaomeng J. Wangchemistry Degrees
Chemistry
#4602
World Rank
#5686
Historical Rank
Computational Chemistry
#50
World Rank
#50
Historical Rank
Organic Chemistry
#765
World Rank
#862
Historical Rank
Download Badge
Chemistry
Shaomeng J. Wang's Degrees
- PhD Pharmaceutical Sciences University of California, San Francisco
- Bachelors Pharmacy Fudan University
Why Is Shaomeng J. Wang Influential?
(Suggest an Edit or Addition)Shaomeng J. Wang's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Further development and validation of empirical scoring functions for structure-based binding affinity prediction (2002) (991)
- Therapeutic Targeting of BET Bromodomain Proteins in Castration-Resistant Prostate Cancer (2014) (765)
- Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition (2008) (636)
- Structure-based design of potent non-peptide MDM2 inhibitors. (2005) (569)
- Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. (2009) (566)
- Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. (2013) (543)
- Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization. (2004) (464)
- Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. (2004) (339)
- Targeting the MDM2-p53 Interaction for Cancer Therapy (2008) (307)
- Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. (2006) (278)
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo. (2019) (264)
- Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia. (2014) (237)
- A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. (2011) (230)
- Discovery of a Small-Molecule Degrader of Bromodomain and Extra-Terminal (BET) Proteins with Picomolar Cellular Potencies and Capable of Achieving Tumor Regression (2017) (227)
- SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression. (2014) (225)
- Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair (2006) (219)
- A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. (2013) (216)
- Design of triazole-stapled BCL9 α-helical peptides to target the β-catenin/B-cell CLL/lymphoma 9 (BCL9) protein-protein interaction. (2012) (198)
- Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer. (2019) (197)
- Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges. (2017) (192)
- SM-164: a novel, bivalent Smac mimetic that induces apoptosis and tumor regression by concurrent removal of the blockade of cIAP-1/2 and XIAP. (2008) (190)
- Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent Smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. (2007) (189)
- Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair (2008) (185)
- Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. (2013) (181)
- Targeting Bcl-2 and Bcl-XL with nonpeptidic small-molecule antagonists. (2003) (173)
- Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. (2003) (172)
- (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. (2005) (170)
- Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction. (2009) (160)
- Targeting apoptosis pathways for new cancer therapeutics. (2014) (160)
- Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. (2018) (159)
- Small-molecule SMAC mimetics as new cancer therapeutics. (2014) (156)
- Discovery of MD-224 as a First-in-Class, Highly Potent, and Efficacious Proteolysis Targeting Chimera Murine Double Minute 2 Degrader Capable of Achieving Complete and Durable Tumor Regression. (2018) (153)
- (-)-Gossypol enhances response to radiation therapy and results in tumor regression of human prostate cancer. (2005) (151)
- Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1 (2007) (148)
- Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma. (2005) (147)
- Structure-based design of potent, conformationally constrained Smac mimetics. (2004) (146)
- High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. (2013) (145)
- (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions. (2007) (138)
- The FHA and BRCT domains recognize ADP-ribosylation during DNA damage response (2013) (138)
- A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species. (2006) (135)
- Structure-based design, synthesis, and evaluation of conformationally constrained mimetics of the second mitochondria-derived activator of caspase that target the X-linked inhibitor of apoptosis protein/caspase-9 interaction site. (2004) (135)
- Chimeric (α/β + α)-Peptide Ligands for the BH3-Recognition Cleft of Bcl-xL: Critical Role of the Molecular Scaffold in Protein Surface Recognition (2005) (134)
- Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2 (2020) (133)
- Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER). (2019) (132)
- In vitro Effects of the BH3 Mimetic, (−)-Gossypol, on Head and Neck Squamous Cell Carcinoma Cells (2004) (131)
- Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer. (2017) (130)
- BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer (2016) (129)
- Reversal of cisplatin resistance with a BH3 mimetic, (−)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL (2005) (129)
- Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug release. (2010) (128)
- CSAR Benchmark Exercise of 2010: Combined Evaluation Across All Submitted Scoring Functions (2011) (128)
- (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. (2006) (124)
- Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists (2007) (121)
- RNF111-dependent neddylation activates DNA damage-induced ubiquitination. (2013) (120)
- Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-kappaB and CXC chemokines. (2005) (119)
- CSAR Benchmark Exercise of 2010: Selection of the Protein–Ligand Complexes (2011) (110)
- Discovery of 4-((3′R,4′S,5′R)-6″-Chloro-4′-(3-chloro-2-fluorophenyl)-1′-ethyl-2″-oxodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indoline]-5′-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development (2017) (106)
- Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. (2007) (106)
- Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition. (2009) (101)
- Activating STAT6 mutations in follicular lymphoma. (2015) (101)
- Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands. (2019) (99)
- Design, synthesis, and evaluation of a potent, cell-permeable, conformationally constrained second mitochondria derived activator of caspase (Smac) mimetic. (2006) (99)
- Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2 (2004) (93)
- Structure-Based Discovery of SD-36 as a Potent, Selective and Efficacious PROTAC Degrader of STAT3 Protein. (2019) (92)
- Design of small-molecule peptidic and nonpeptidic Smac mimetics. (2008) (92)
- Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. (2010) (87)
- Preclinical studies of Apogossypolone: a new nonpeptidic pan small-molecule inhibitor of Bcl-2, Bcl-XL and Mcl-1 proteins in Follicular Small Cleaved Cell Lymphoma model (2008) (86)
- Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer (2008) (85)
- Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as New Cancer Therapeutics (2013) (85)
- Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment (2020) (84)
- Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes. (2006) (82)
- Antiangiogenic effect of TW37, a small-molecule inhibitor of Bcl-2. (2006) (81)
- An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals (2009) (80)
- TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. (2009) (80)
- Combined Targeting of Epidermal Growth Factor Receptor, Signal Transducer and Activator of Transcription-3, and Bcl-XL Enhances Antitumor Effects in Squamous Cell Carcinoma of the Head and Neck (2008) (77)
- Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. (2017) (76)
- Pharmacophore-based discovery of substituted pyridines as novel dopamine transporter inhibitors. (2003) (76)
- Structure-Based Design of γ-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors. (2015) (75)
- Acylpyrogallols as inhibitors of antiapoptotic Bcl-2 proteins. (2008) (74)
- Structure-based design, synthesis, evaluation, and crystallographic studies of conformationally constrained Smac mimetics as inhibitors of the X-linked inhibitor of apoptosis protein (XIAP). (2008) (73)
- Therapeutic Potential and Molecular Mechanism of a Novel, Potent, Nonpeptide, Smac Mimetic SM-164 in Combination with TRAIL for Cancer Treatment (2011) (71)
- BM-1197: A Novel and Specific Bcl-2/Bcl-xL Inhibitor Inducing Complete and Long-Lasting Tumor Regression In Vivo (2014) (70)
- Design of Small‐Molecule Peptidic and Nonpeptidic Smac Mimetics (2009) (69)
- Design of small-molecule Smac mimetics as IAP antagonists. (2010) (68)
- Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review. (2019) (68)
- Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapeutics (2012) (67)
- Design of Bcl-2 and Bcl-xL inhibitors with subnanomolar binding affinities based upon a new scaffold. (2012) (66)
- Identification of a Mutant α1 Na/K-ATPase That Pumps but Is Defective in Signal Transduction* (2013) (64)
- Nonpeptidic Small-Molecule Inhibitor of Bcl-2 and Bcl-XL, (−)-Gossypol, Enhances Biological Effect of Genistein Against BxPC-3 Human Pancreatic Cancer Cell Line (2005) (63)
- Discovery of a Highly Potent, Cell-Permeable Macrocyclic Peptidomimetic (MM-589) Targeting the WD Repeat Domain 5 Protein (WDR5)-Mixed Lineage Leukemia (MLL) Protein-Protein Interaction. (2017) (61)
- MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. (2010) (61)
- A Network of Substrates of the E3 Ubiquitin Ligases MDM2 and HUWE1 Control Apoptosis Independently of p53 (2013) (60)
- Importance of ligand reorganization free energy in protein-ligand binding-affinity prediction. (2009) (59)
- MLL1 Inhibition Reprograms Epiblast Stem Cells to Naive Pluripotency. (2016) (57)
- A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation (2017) (57)
- Elucidation of Resistance Mechanisms to Second-Generation ALK Inhibitors Alectinib and Ceritinib in Non–Small Cell Lung Cancer Cells (2016) (57)
- Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. (2018) (57)
- M-score: a knowledge-based potential scoring function accounting for protein atom mobility. (2006) (56)
- Design of Chemically Stable, Potent, and Efficacious MDM2 Inhibitors That Exploit the Retro-Mannich Ring-Opening-Cyclization Reaction Mechanism in Spiro-oxindoles (2014) (53)
- Retracted: TW‐37, a small‐molecule inhibitor of Bcl‐2, inhibits cell growth and invasion in pancreatic cancer (2008) (52)
- Design, synthesis, and characterization of new embelin derivatives as potent inhibitors of X-linked inhibitor of apoptosis protein. (2006) (52)
- Interaction of a cyclic, bivalent smac mimetic with the x-linked inhibitor of apoptosis protein. (2008) (51)
- Hydrophobic Binding Hot Spots of Bcl-xL Protein-Protein Interfaces by Cosolvent Molecular Dynamics Simulation. (2011) (51)
- MI-219-Zinc Combination: a new Paradigm in MDM2 Inhibitor Based Therapy (2010) (50)
- Synthesis of spirooxindoles via asymmetric 1,3-dipolar cycloaddition (2005) (50)
- p53-mediated heterochromatin reorganization regulates its cell fate decisions (2012) (48)
- A covalently bound inhibitor triggers EZH2 degradation through CHIP‐mediated ubiquitination (2017) (48)
- AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer (2012) (48)
- Design and characterization of bivalent Smac-based peptides as antagonists of XIAP and development and validation of a fluorescence polarization assay for XIAP containing both BIR2 and BIR3 domains. (2008) (47)
- Structure-based discovery of BM-957 as a potent small-molecule inhibitor of Bcl-2 and Bcl-xL capable of achieving complete tumor regression. (2012) (47)
- Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity. (2012) (47)
- Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases (2011) (46)
- Design and synthesis of a new, conformationally constrained, macrocyclic small-molecule inhibitor of STAT3 via 'click chemistry'. (2007) (46)
- Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo (2015) (45)
- Potent, orally bioavailable diazabicyclic small-molecule mimetics of second mitochondria-derived activator of caspases. (2008) (45)
- A small molecule compound inhibits AKT pathway in ovarian cancer cell lines. (2006) (42)
- -(-)Gossypol promotes the apoptosis of bladder cancer cells in vitro. (2008) (42)
- Apogossypolone, a nonpeptidic small molecule inhibitor targeting Bcl-2 family proteins, effectively inhibits growth of diffuse large cell lymphoma cells in vitro and in vivo (2008) (42)
- Proerectile Effects of Dopamine D2-Like Agonists Are Mediated by the D3 Receptor in Rats and Mice (2009) (41)
- Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity. (2011) (40)
- Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins. (2007) (40)
- MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner12 (2016) (39)
- High-Affinity Peptidomimetic Inhibitors of the DCN1-UBC12 Protein-Protein Interaction. (2018) (39)
- Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. (2021) (38)
- Identification of the Fibroblast Growth Factor (FGF)-interacting Domain in a Secreted FGF-binding Protein by Phage Display* (2006) (38)
- Targeting Mll1 H3K4 methyltransferase activity to guide cardiac lineage specific reprogramming of fibroblasts (2016) (38)
- TW-37, a small-molecule inhibitor of Bcl-2, mediates S-phase cell cycle arrest and suppresses head and neck tumor angiogenesis (2009) (38)
- Tranylcypromine Substituted cis-Hydroxycyclobutylnaphthamides as Potent and Selective Dopamine D3 Receptor Antagonists (2014) (38)
- Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis (2008) (38)
- Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein Interaction. (2018) (38)
- Structure-based design of flavonoid compounds as a new class of small-molecule inhibitors of the anti-apoptotic Bcl-2 proteins. (2007) (37)
- A small molecule that disrupts Mdm2-p53 binding activates p53, induces apoptosis, and sensitizes lung cancer cells to chemotherapy (2008) (37)
- Structure-based design, synthesis and biochemical testing of novel and potent Smac peptido-mimetics. (2005) (37)
- Targeting Inhibitors of Apoptosis Proteins (IAPs) For New Breast Cancer Therapeutics (2012) (36)
- Split Renilla Luciferase Protein Fragment-assisted Complementation (SRL-PFAC) to Characterize Hsp90-Cdc37 Complex and Identify Critical Residues in Protein/Protein Interactions* (2010) (36)
- MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program (2016) (35)
- LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFα expression and receptor tyrosine kinase signaling. (2012) (35)
- Targeting Inhibitor of Apoptosis Proteins Protects from Bleomycin-Induced Lung Fibrosis. (2016) (35)
- Spiromastilactones: A new class of influenza virus inhibitors from deep-sea fungus. (2016) (35)
- Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. (2010) (35)
- Design, synthesis, and evaluation of tricyclic, conformationally constrained small-molecule mimetics of second mitochondria-derived activator of caspases. (2008) (35)
- Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. (2021) (35)
- E2F1-Dependent Oncogenic Addiction of Melanoma Cells to MDM2 (2011) (34)
- A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo (2020) (34)
- A potent and highly efficacious Bcl-2/Bcl-xL inhibitor. (2013) (34)
- Analysis of Flexibility and Hotspots in Bcl-xL and Mcl-1 Proteins for the Design of Selective Small-Molecule Inhibitors. (2012) (34)
- Analysis of the interaction of BCL9 with beta-catenin and development of fluorescence polarization and surface plasmon resonance binding assays for this interaction. (2009) (33)
- Design, synthesis, and evaluation of potent, nonpeptidic mimetics of second mitochondria-derived activator of caspases. (2009) (33)
- Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis (2012) (33)
- Behavioral sensitization to cocaine in rats: evidence for temporal differences in dopamine D3 and D2 receptor sensitivity (2011) (32)
- A potent bivalent Smac mimetic (SM-1200) achieving rapid, complete, and durable tumor regression in mice. (2013) (32)
- A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer (2016) (32)
- Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor. (2017) (32)
- Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer. (2007) (32)
- Design, synthesis, and evaluation of potent and selective ligands for the dopamine 3 (D3) receptor with a novel in vivo behavioral profile. (2008) (31)
- Cyclopeptide Smac mimetics as antagonists of IAP proteins. (2010) (31)
- BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice. (2015) (30)
- Computational analysis of protein hotspots. (2010) (30)
- Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer (2020) (29)
- Efficient synthesis of isoflavone analogues via a Suzuki coupling reaction (2005) (29)
- Pyrimido[4,5-d]pyrimidin-4(1H)-one derivatives as selective inhibitors of EGFR threonine790 to methionine790 (T790M) mutants. (2013) (29)
- Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma (2016) (29)
- Potent and Selective Small-Molecule Inhibitors of cIAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells (2014) (28)
- Bivalent Smac mimetics with a diazabicyclic core as highly potent antagonists of XIAP and cIAP1/2 and novel anticancer agents. (2012) (27)
- Effects of pramipexole on the reinforcing effectiveness of stimuli that were previously paired with cocaine reinforcement in rats (2011) (27)
- Therapeutic Inhibition of the MDM2–p53 Interaction Prevents Recurrence of Adenoid Cystic Carcinomas (2016) (26)
- Design, synthesis, and evaluation of peptidomimetics containing Freidinger lactams as STAT3 inhibitors. (2009) (26)
- Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide. (2010) (25)
- Smac Mimetic Compounds Potentiate Interleukin-1β-mediated Cell Death* (2010) (25)
- The pre-clinical development of MDM2 inhibitors in chronic lymphocytic leukemia uncovers a central role for p53 status in sensitivity to Mdm2 inhibitor-mediated apoptosis (2008) (24)
- Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment (2015) (23)
- Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer (2016) (23)
- AT‐101 (R‐(−)‐gossypol acetic acid) enhances the effectiveness of androgen deprivation therapy in the VCaP prostate cancer model (2010) (23)
- The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated anti-tumor immunity (2021) (22)
- Anti-oxidant treatment enhances anti-tumor cytotoxicity of (-)-gossypol (2008) (22)
- Targeting theMDM 2p 53 Interaction for Cancer Therapy (2008) (22)
- Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility. (2006) (22)
- BRD4 Levels Determine the Response of Human Lung Cancer Cells to BET Degraders That Potently Induce Apoptosis through Suppression of Mcl-1 (2020) (22)
- Follicular lymphoma–associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR (2019) (21)
- Enantiomerically pure hexahydropyrazinoquinolines as potent and selective dopamine 3 subtype receptor ligands. (2005) (21)
- Computational elucidation of the structural basis of ligand binding to the dopamine 3 receptor through docking and homology modeling. (2006) (20)
- Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer (2019) (20)
- In vitro Effects of the BH 3 Mimetic , ( )-Gossypol , on Head and Neck Squamous Cell Carcinoma Cells (2004) (19)
- SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells (2015) (19)
- Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. (2017) (19)
- Metronomic small molecule inhibitor of Bcl-2 (TW-37) is antiangiogenic and potentiates the antitumor effect of ionizing radiation. (2010) (19)
- Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor. (2018) (19)
- Casein kinase-1γ1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3 (2019) (18)
- Design, synthesis and structure-activity relationship studies of hexahydropyrazinoquinolines as a novel class of potent and selective dopamine receptor 3 (D3) ligands. (2005) (18)
- Changing the Apoptosis Pathway through Evolutionary Protein Design. (2019) (18)
- CJ-1639: A Potent and Highly Selective Dopamine D3 Receptor Full Agonist. (2011) (17)
- Formation of a novel reversible cytochrome P450 spectral intermediate: role of threonine 303 in P450 2E1 inactivation. (2004) (17)
- Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM‐406/AT‐406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer (2013) (16)
- A sequence variant in the phospholipase C epsilon C2 domain is associated with esophageal carcinoma and esophagitis (2011) (16)
- Metronomic dosing of BH3 mimetic small molecule yields robust antiangiogenic and antitumor effects. (2012) (16)
- Design of High-Affinity Stapled Peptides To Target the Repressor Activator Protein 1 (RAP1)/Telomeric Repeat-Binding Factor 2 (TRF2) Protein-Protein Interaction in the Shelterin Complex. (2016) (16)
- Discovery of New 4-Indolyl Quinazoline Derivatives as Highly Potent and Orally Bioavailable P-Glycoprotein Inhibitors. (2021) (16)
- Blockade of AKT activation in prostate cancer cells with a small molecule inhibitor, 9-chloro-2-methylellipticinium acetate (CMEP). (2007) (16)
- Ablation of Cancer Stem Cells by Therapeutic Inhibition of the MDM2–p53 Interaction in Mucoepidermoid Carcinoma (2018) (15)
- The Direct Molecular Target for Imipridone ONC201 Is Finally Established. (2019) (15)
- A systematic analysis of the effect of small-molecule binding on protein flexibility of the ligand-binding sites. (2005) (14)
- Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein Interaction. (2019) (14)
- Role of BET proteins in castration-resistant prostate cancer. (2016) (14)
- A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells (2007) (14)
- Design, Synthesis and Characterization of New Embelin Derivatives as Potent Inhibitors of X-Linked Inhibitor of Apoptosis Protein. (2007) (13)
- EEDi-5285: An Exceptionally Potent, Efficacious, and Orally Active Small-Molecule Inhibitor of Embryonic Ectoderm Development. (2020) (13)
- Chimeric (alpha/beta + alpha)-peptide ligands for the BH3-recognition cleft of Bcl-XL: critical role of the molecular scaffold in protein surface recognition. (2005) (13)
- Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma (2016) (12)
- Chemical suppression of specific C-C chemokine signaling pathways enhances cardiac reprogramming (2019) (12)
- Design and synthesis of a 1,5-diazabicyclo[6,3,0] dodecane amino acid derivative as a novel dipeptide reverse-turn mimetic (2006) (12)
- High-affinity and selective dopamine D₃ receptor full agonists. (2012) (12)
- In Vitro Metabolism of 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin in Human Liver Microsomes (2011) (12)
- Follicular Lymphoma–associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation (2021) (12)
- Discovery of M-808 as a Highly Potent, Covalent, Small-Molecule Inhibitor of the Menin-MLL Interaction with Strong In Vivo Antitumor Activity. (2020) (11)
- Discovery of substituted 3,4-diphenyl-thiazoles as a novel class of monoamine transporter inhibitors through 3-D pharmacophore search using a new pharmacophore model derived from mazindol. (2002) (11)
- IAPs protect host target tissues from graft-versus-host disease in mice. (2017) (11)
- SD-91 as A Potent and Selective STAT3 Degrader Capable of Achieving Complete and Long-Lasting Tumor Regression. (2021) (10)
- BET protein degradation triggers DR5-mediated immunogenic cell death to suppress colorectal cancer and potentiate immune checkpoint blockade (2021) (10)
- BH3-mimetic small molecule inhibits the growth and recurrence of adenoid cystic carcinoma. (2015) (10)
- Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED). (2017) (10)
- Topography of transcriptionally active chromatin in glioblastoma (2021) (10)
- Erratum: Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer (Cancer Cell (2017) 31(4) (532–548.e7)(S1535610817300600)(10.1016/j.ccell.2017.02.017)) (2017) (10)
- Induction of p53 suppresses chronic myeloid leukemia (2017) (10)
- Cyclic Peptidic Mimetics of Apollo Peptides Targeting Telomeric Repeat Binding Factor 2 (TRF2) and Apollo Interaction. (2018) (9)
- 338 BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity (2014) (9)
- Discovery of EEDi-5273 as an Exceptionally Potent and Orally Efficacious EED Inhibitor Capable of Achieving Complete and Persistent Tumor Regression. (2021) (9)
- Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor Regression. (2021) (8)
- Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells. (2007) (8)
- Identification of Novel Neuroprotective Agents Using Pharmacophore Modeling (2005) (8)
- p27 degradation by an ellipticinium series of compound via ubiquitin-proteasome pathway (2007) (8)
- Pramipexole Derivatives as Potent and Selective Dopamine D3 Receptor Agonists with Improved Human Microsomal Stability (2014) (8)
- Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity (2021) (7)
- A Pilot Study on Imaging of 18F-Alfatide-RGD PET/CT in Patients With Glioma (2015) (7)
- Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. (2020) (7)
- Combined Targeting of EGFR , STAT 3 , and Bcl-XL Enhances Antitumor Effects in Squamous Cell Carcinoma of the Head and Neck (2008) (6)
- An efficient synthesis of optically pure (S)-2-functionalized 1,2,3,4-tetrahydroquinoline (2004) (6)
- Optimization and validation of mitochondria-based functional assay as a useful tool to identify BH3-like molecules selectively targeting anti-apoptotic Bcl-2 proteins (2013) (6)
- Efficient synthesis of phosphotyrosine building blocks using imidazolium trifluoroacetate (2009) (5)
- Design and Synthesis of a New, Conformationally Constrained, Macrocyclic Small-Molecule Inhibitor of STAT3 via “Click Chemistry”. (2007) (5)
- Targeting the MDM 2 – p 53 Protein – Protein Interaction for New Cancer Therapy : Progress and Challenges (2017) (5)
- Correction to CSAR Benchmark Exercise of 2010: Selection of the Protein–Ligand Complexes (2011) (5)
- Expression of anti-apoptosis genes determines the response of adrenal cancer to apoptosis-inducing chemotherapy. (2010) (5)
- Design, synthesis, and evaluation of hexahydrobenz[f]isoquinolines as a novel class of dopamine 3 receptor ligands. (2004) (5)
- Discovery of Potent Small-Molecule Inhibitors of MLL Methyltransferase. (2020) (5)
- Targeting DCN1-UBC12 Protein-Protein Interaction for Regulation of Neddylation Pathway. (2020) (5)
- Potency and Selectivity Optimization of Tryptophanol‐Derived Oxazoloisoindolinones: Novel p53 Activators in Human Colorectal Cancer (2020) (5)
- Characterizing the Therapeutic Potential of a Potent BET Degrader in Merkel Cell Carcinoma1 (2019) (4)
- Small Molecule Antagonists Targeting Growth Factors/Receptors (1997) (4)
- The novel BET degrader, QCA570, is highly active against the growth of human NSCLC cells and synergizes with osimertinib in suppressing osimertinib-resistant EGFR-mutant NSCLC cells. (2022) (4)
- Correction to "Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein". (2020) (4)
- Case Study: discovery of inhibitors of the MDM2-p53 protein-protein interaction. (2015) (4)
- Structure-based design of conformationally constrained cyclic peptidomimetics to target the MLL1-WDR5 protein–protein interaction as inhibitors of the MLL1 methyltransferase activity (2015) (4)
- A Network of Substrates of the E 3 Ubiquitin Ligases MDM 2 and HUWE 1 Control Apoptosis Independently of p 53 (2013) (4)
- Targeting MLL 1 H 3 K 4 methyltransferase activity in MLL leukemia (2014) (4)
- Abstract LB-204: Highly potent and optimized small-molecule inhibitors of MDM2 achieve complete tumor regression in animal models of solid tumors and leukemia. (2011) (3)
- 643 Radiosensitization of human prostate cancer by natural polyphenol inhibitor of Bcl-2/XL, (−)-gossypol, results in tumor regression (2004) (3)
- Correction to Design of Bcl-2 and Bcl-xL Inhibitors with Subnanomolar Binding Affinities Based upon a New Scaffold. (2012) (3)
- Abstract 4648: In vitro characterization of spiro-oxindole-based modulators of the MDM2-p53 interaction and their interspecies selectivity. (2012) (3)
- Evaluation of TW-37, a pan Bcl-2 Proteins Small-Molecule Inhibitor, Against Spectrum of Human B-Cell Lines and Patient-Derived Samples. (2007) (3)
- Design and synthesis of a potent biotinylated Smac mimetic (2005) (2)
- Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models (2022) (2)
- A potent small-molecule inhibitor of the DCN1-UBC12 interaction that selectively blocks cullin 3 neddylation (2017) (2)
- Enhancing Cardiac Reprogramming by Suppressing Specific C-C Chemokine Signaling Pathways (2019) (2)
- Lisaftoclax (APG-2575) is a Novel BCL-2 Inhibitor with Robust Antitumor Activity in Preclinical Models of Hematologic Malignancy. (2022) (2)
- Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. (2019) (2)
- Discovery and characterization of new small-molecule inhibitors of Mcl-1 by high-throughput screening (2008) (2)
- Abstract 73: Development of APG-3526 as a novel and highly efficacious MCL-1 inhibitor (2020) (2)
- 544 Preclinical studies of a dual Bcl-2/Bcl-xL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity (2014) (2)
- p53 inhibits Bmi-1-driven self-renewal and defines salivary gland cancer stemness. (2022) (2)
- Can a Novel 18F-ALF-NOTA-PRGD2 PET/CT Predict the Treatment Sensitivity of Concurrent Chemoradiation Therapy in Patients With Newly Diagnostic Glioblastoma? (2015) (2)
- Abstract 2529: Debio 1143 synergizes with taxanes, topoisomerase and bromodomain inhibitors to inhibit growth of lung adenocarcinoma (2015) (1)
- Targeting p53-mdm2 interaction using a potent mdm2 inhibitor to overcome cisplatin resistance in head and neck squamous cell carcinoma (2007) (1)
- Correction to: Targeted degradation of activating estrogen receptor α ligand-binding domain mutations in human breast cancer (2020) (1)
- China multicenter study of sentinel node biopsy substituting axillary node dissection: CBCSG-01 trial (2008) (1)
- Apatinib Plus Radiation Therapy or Not in Chemotherapy-Refractory Recurrent or Metastatic Oral Squamous Cell Carcinoma: A Pilot Study (2018) (1)
- Potentiation of apoptosis inducing activity of BL-193, an inhibitor of Bcl-XL protein, by genistein in pancreatic cancer cells (2004) (1)
- 078 The effect of LPS on neutrophil extracellular trap-induced Th17 polarization is IL-6 and STAT3-Dependent (2020) (1)
- Multi-dimensional analyses identify genes of high priority for pancreatic cancer research (2021) (1)
- A novel BH3 mimetic reveals a MAPK-dependent mechanism of melanoma cell survival controlled by p53 and reactive oxygen species (2006) (1)
- Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1 (2022) (1)
- Improved Anti-Leukemic Pre-Clinical Efficacy of a Protac Based MDM2 Degrader in a Large AML Cohort (2019) (1)
- In Vitro Metabolism of 17-( dimethylaminoethylamino )-17-demethoxygeldanamycin ( 17-DMAG ) in Human Liver Microsomes (2010) (1)
- Synthesis of Spirooxindoles via Asymmetric 1,3-Dipolar Cycloaddition. (2005) (1)
- Therapeutic Strategies to Activate p53 (2022) (1)
- Abstract 5795: Functional and mechanistic interrogation of BET Bromodomain degraders for the treatment of metastatic castration resistant prostate cancer (2017) (1)
- AML-397: Preclinical Efficacy of a PROTAC-based MDM2 Degrader in AML models (2020) (1)
- A novel orally active MDM2 inhibitor (MI-219) activates the p53 pathway and is selectively toxic to tumor cells (2007) (1)
- Radiomic CT Features for Evaluation of PD-L1, CD8+TILs and Foxp3+TILs Expression Status in Patients with Stage I NSCLC (2017) (1)
- Therapeutics , Targets , and Chemical Biology LRIG 1 Modulates Cancer Cell Sensitivity to Smac Mimetics by Regulating TNF a Expression and Receptor Tyrosine Kinase Signaling (2012) (1)
- Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis (2022) (1)
- 384 POSTER Smac mimetics selectively induce apoptosis in cancer cells but not in normal cells (2006) (1)
- Abstract 5074: Therapeutic targeting of bromodomain and extra-terminal proteins degradation in triple-negative breast cancer (2017) (1)
- Gossypol(-), a potent small molecule inhibitor of Bcl-2/xl, improves response to radiation therapy and results in tumor regression of human prostate cancer (2004) (1)
- In vivo tumor regression achieved by a potent bivalent Smac mimetic (SM-164) in combination with TRAIL (2007) (1)
- CURCUMIN SENSITIZES PANCREATIC CANCER CELLS TO APOG2 INDUCED KILLING (2006) (1)
- Identification of p53 Aberration-Dependent as Well as Non-p53-Mediated Resistance to MDM2 Inhibitors in Acute Myelogenous Leukemia. (2008) (0)
- Abstract 2664: Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors (2022) (0)
- Changing the Ap through Evolutio (2019) (0)
- Abstract 1231: Identification of selective Brd4 degrader for cancer treatment (2021) (0)
- Prediction of Membrane Binding, Orientation and Permeability of Peptide-like Molecules Using a Continuum Model of the Lipid Bilayer (2009) (0)
- Perioperative chemotherapy with oxaliplatin/5-fluorouracil/leucovorin (FOLFOX7) for locally advanced gastric cancer: Final results of a prospective multicenter phase II study (BJSA-01) with 2 years follow-up. (2010) (0)
- BI-33, a novel and potent pan-Bcl-2 inhibitor, induces apoptosis in cancer cells and shows combinational effect with chemo drugs (2007) (0)
- Superior Pre-Clinical Efficacy of Novel Protac Based BET Degrader in a Large Acute Myeloid Leukemia Cohort (2019) (0)
- Synthesis of Symmetrical Dimeric Dicarboxylic Acid Linked Peptides on Solid Support (2006) (0)
- Abstract C250: Concurrent targeting Bcl-2/Bcl-xL and MDM2 as a new therapeutic strategy for acute leukemia. (2013) (0)
- TW-37, A NONPEPTIDIC SMALL-MOLECULE INHIBITOR OF BCL-2, INHIBITS INVASION AND ANGIOGENESIS IN PANCREATIC CANCER (2007) (0)
- Case Study: Inhibitors of the MDM2‐p53 Protein–Protein Interaction (2010) (0)
- 87 Critical difference in development of acquired resistance to MDM2 inhibitor SAR405838 in vitro and in vivo (2014) (0)
- Abstract 1754: Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models (2018) (0)
- Abstract LB-265: Patient-derived xenografts from advanced luminal-type breast cancer: insights into endocrine therapy resistance. (2013) (0)
- Abstract 3939: Preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918/EEDi-5273 for cancer therapy (2022) (0)
- Predictive capacity of a new staging system for upper aerodigestive tract NK/T-cell lymphoma (2008) (0)
- 164 POSTER In vitro and in vivo evaluation of orally available potent and selective small-molecule antagonists of the MDM2-p53 interaction in multiple models of human cancer (2006) (0)
- Abstract 2672: Characterization of Hsp90/Cdc37 interaction and their critical residues using luciferase fragment complementation imaging (2010) (0)
- Circulating tumor cells (CTC) as a prognostic and predictive factor in Lung Cancer Patients–a pilot study in PUMCH (2008) (0)
- Abstract 5441: Debio 1143, an oral antagonist of the inhibitor of apoptosis proteins, synergistically enhances the effects of multiple standard of care agents in human lung cancer models (2014) (0)
- B and CXC Chemokines κ Nuclear Factor-Bcl-2 Acts in a Proangiogenic Signaling Pathway through (2005) (0)
- Abstract 5083: A novel and highly efficacious small-molecule degrader of BET-BRD proteins for the treatment of acute leukemia (2017) (0)
- Abstract 2786: Potent inhibition of human liposarcoma cell growth and survival by novel modulators of the MDM2-p53 interaction (2012) (0)
- TITLE : Structure-Based Approach for Discovery of Small Molecule Inhibitors Targeted at AKT PRINCIPAL INVESTIGATOR : (2007) (0)
- Abstract ED01-01: Use of natural products as the scaffolds for the design of molecularly targeted agents for cancer treatment and prevention (2008) (0)
- TRANSPLANTATION BET bromodomain inhibition suppresses graft-versus-host disease after allogeneic bone marrow transplantation in mice (2015) (0)
- Abstract 1036: Discovery of a highly potent, efficacious and orally active small-molecule inhibitor of embryonic ectoderm development (EED) (2020) (0)
- Abstract 1960: Targeted androgen receptor (AR) protein degradation for the treatment of metastatic castration-resistant prostate cancer (mCRPC) (2020) (0)
- Chapter 11 Recent Advances in Design of Small-Molecule Ligands to Target Protein–Protein Interactions (2006) (0)
- Optimizing the oxazoloisoindolinone family: Identification and biological evaluation of a potent and selective indole-based p53 activator in human colorectal cancer (2020) (0)
- POTENTIATION OF APOPTOSIS INDUCING ACTIVITY OF BL-193, A NONPEPTIDIC SMALL-MOLECULE INHIBITOR OF BCL-2/BCL-XL PROTEINS, BY GENISTEIN IN PANCREATIC CANCER CELLS. (2004) (0)
- TW-37 INHIBITS CELL GROWTH AND INDUCES APOPTOSIS IN PANCREATIC CANCER: INVOLVEMENT OF NOTCH-1 SIGNALING PATHWAY (2008) (0)
- Abstract LB-256: Targeting MLL1 methyltransferase activity for treatment of acute leukemia with MLL1 rearrangement (2012) (0)
- Design and Evaluation of Cyclized Small Peptides Derived from Her-2 as a Novel Therapeutic Strategy for Breast Cancer (2004) (0)
- Functional Analyses of BTK Mutations in Follicular Lymphoma (2017) (0)
- Design, Synthesis and Structure—Activity Relationship Studies of Hexahydropyrazinoquinolines as a Novel Class of Potent and Selective Dopamine Receptor 3 (D3) Ligands. (2005) (0)
- Abstract 307: Targeting BCL-2 and BCL-xL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models (2018) (0)
- A synergistic combination of (-) -gossypol with docetaxel or paclitaxel for the treatment of cancer. (2002) (0)
- Abstract A16: A drug combination screen identifies taxanes as synergistic agents with the oral IAP inhibitor Debio 1143 in non-small cell lung cancer cells. (2013) (0)
- Production de co-cristaux de gossypol (2007) (0)
- Efficient Synthesis of Isoflavone Analogues via a Suzuki Coupling Reaction. (2005) (0)
- A Pilot Study of 18F-ALF-NOTA-PRGD2 PET/CT Imaging in Detecting Lymph Node Metastases in Patients With Non-Small Cell Lung Cancer (2016) (0)
- Abstract 4535: MDM2 inhibitor MI-319 in combination with cisplatin/oxaliplatin is an effective treatment for pancreatic cancer independent of p53 function (2010) (0)
- Debio-1143. Inhibitor of apoptosis protein (IAP) antagonist, Cancer therapy (2017) (0)
- Abstract 4521: Discovery of novel small molecule inhibitors of the antiapoptotic protein Mcl-1 through high-throughput screening approach (2010) (0)
- 254 INVITED Small molecule inhibitors of the human MDM2-p53 interaction as anticancer agents (2008) (0)
- Abstract 1250: Antitumor activities of CD161, a structurally novel and orally bioavailable BET inhibitor, in leukemia and triple negative breast cancer cellsin vitroandin vivo (2016) (0)
- Award Number: W81XWH-05-1-0128 TITLE: Preclinical Testing the Therapeutic Potential of a Potent and Novel Small- molecule Inhibitor of Bcl-2 as a Novel Therapy for Hormone-refractory Prostate Cancer (2007) (0)
- Reactivation of p 53 by MDM 2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer (2016) (0)
- Abstract 4731: Cytotoxic versus cytostatic effects in tumor models by spiro-oxindole-based modulators of the MDM2-p53 interaction (2012) (0)
- Abstract 2123: Chromatin profiling of glioblastoma tissues identifies core oncogenic dependency and therapeutic opportunities (2021) (0)
- Predictive Role of Integrin αvβ3 Imaging with 18 F-Alfatide Micro-PET in Lewis Lung Carcinoma Tumor-Bearing C57BL/6 Mice After Radiation Therapy (2017) (0)
- A Pilot Study: Predictive Value of Early Responses With 18F-Alfatide RGD PET/CT in Locally Advanced Non-Small Cell Lung Cancer Treated With Concurrent Chemoradiation Therapy (2016) (0)
- 412 Antitumor Activity of BM-1197, a Dual Inhibitor of Bcl-2 and Bcl-xL, in Small Cell Lung Cancer Tumors (2012) (0)
- “Development of Small-Molecule STAT6 Degraders” (2019) (0)
- Probing Distinct Oncogene Addiction By Novel BCL-2 Inhibitors (2018) (0)
- Analysis of 54 Follicular Lymphomas By Whole Exome Sequencing Identifies Multiple Novel Recurrently Mutated Pathways (2015) (0)
- Abstract 1001: Functional and mechanistic interrogation of androgen receptor degraders for the treatment of metastatic castration resistant prostate cancer (2019) (0)
- Three-Component Tandem Reaction to Synthesize Tetrasubstituted Olefins (2006) (0)
- Targeting the Apoptotic Pathway by TW-37, a Novel Bcl-2 Family Small Molecule Inhibitor, In CLL Primary Samples (2010) (0)
- Abstract 3254: Novel bivalent Smac mimetics as a new class of anticancer agents (2011) (0)
- Inhibition of AKT Oncogenic Pathway in Endometrial Cancer Cells (2003) (0)
- Targeting p53 in CML Chronic Phase Leukemia Stem Cells (2015) (0)
- Synthesis of Spiro-oxindole MDM2 Inhibitors (2006) (0)
- Design of cyclic Smac mimetic peptide and in vitro characterization of its complex with X-linked inhibitor of apoptosis protein (XIAP) (2007) (0)
- Dopamine D2/3 receptor partial agonists failed to produce antidepressant‐like effects in the rat forced swim test (2009) (0)
- Therapeutics , Targets , and Chemical Biology Metronomic Dosing of BH 3 Mimetic Small Molecule Yields Robust Antiangiogenic and Antitumor Effects (2012) (0)
- Correction to: Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1 (2022) (0)
- Abstract 5679: Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment (2020) (0)
- Design, synthesis, and evaluation of bivalent conformationally constrained Smac mimetics that concurrently targeting both BIR2 and BIR3 domain of XIAP (2007) (0)
- Preclinical Testing the Therapeutic Potential of a Potent and Novel Small-Molecule Inhibitor of Bcl-2 as a Novel Therapy for Hormone-Refractory Prostate Cancer (2006) (0)
- 138 POSTER Design, synthesis, biochemical and biological evaluations of novel and potent small-molecule inhibitors of STAT3 (2008) (0)
- Functional Analyses of V-Atpase Mutations in Follicular Lymphoma (2016) (0)
- 163 POSTER Characterization of novel Smac mimetics as highly potent and effective antagonists of X-linked inhibitor of apoptosis protein (2006) (0)
- Enhanced Cytotoxicity in Chronic Myeloid Leukemia Primitive Progenitors by the Combined Action of Imatinib and An HDM2-Inhibitor (2008) (0)
- Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models (2022) (0)
- 18F-ALF-NOTA-PRGD2 Positron Emission Tomography/Computed Tomography May Predict Short-term Outcome of Concurrent Chemoradiation Therapy in Patients With Locally Advanced Non-Small Cell Lung Cancer (2016) (0)
- Development and validation of mitochondria-based functional assays to investigate the mechanism of small-molecule inhibitors of Bcl-2/Bcl-xL/Mcl-1 (BH3 mimetics) in cell-free systems (2007) (0)
- Evaluation of a novel MDM-2 inhibitor with cisplatin/oxalipatin for the treatment of pancreatic cancer independent of p53 mutational status. (2010) (0)
- AML-399: A Pan-BET Degrader Shows Broad Pre-Clinical Activity in a Large Acute Myeloid Leukemia Cohort (2020) (0)
- Molecular Heterogeneity as a Basis for Rational Therapeutics in Chronic Lymphocytic Leukemia. (2009) (0)
- Corrigendum to “Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility”: [Bioorg. Med. Chem. Lett. 16 (2006) 443–446] (2006) (0)
- 435 POSTER Therapeutic potential of a potent and selective antagonist of the MDM2-p53 interaction (MI-219) in combination with traditional chemotherapy (2008) (0)
- Changing the Ap Evolutionary Pro (2019) (0)
- 386 CB6, A NOVEL GUT-SELECTIVE BCL-2 INHIBITOR, ATTENUATES INTESTINAL FIBROSIS IN MYBFIBROBLAST CELL MODELS AND THE MOUSE S. TYPHIMURIUM MODEL OF INTESTINAL FIBROSIS (2021) (0)
- Discovery of a Potent and Selective STAT5 PROTAC Degrader with Strong Antitumor Activity In Vivo in Acute Myeloid Leukemia. (2023) (0)
- Small-molecule approach to block p53-MDM2 interaction as a cancer therapeutic strategy (2008) (0)
This paper list is powered by the following services:
